new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




  

Abbott Gmbh & Co Kg patents

Recent patent applications related to Abbott Gmbh & Co Kg. Abbott Gmbh & Co Kg is listed as an Agent/Assignee. Note: Abbott Gmbh & Co Kg may have other listings under different names/spellings. We're not affiliated with Abbott Gmbh & Co Kg, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Abbott Gmbh & Co Kg-related inventors




Date Abbott Gmbh & Co Kg patents (updated weekly) - BOOKMARK this page
10/29/15Extruded nutritional powders having improved emulsion stability and dispersibility and methods of manufacturing same
10/22/15Methods for extruding powered nutritional products using a high shear element
03/12/15Human antibodies that bind human il-12 and methods for producing
12/25/14Substituted oxindole derivatives and their use as vasopressin receptor ligands
10/02/14Solid retard formulations based on solid dispersions
12/05/13Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors
11/28/13Novel carboxylic acid derivatives, their preparation and use
09/19/13Carboxamide compounds and their use as calpain inhibitors
06/13/13Antibodies to receptor of advanced glycation end products (rage) and uses thereof
06/13/13Carboxamide compounds and their use as calpain inhibitors
05/16/13Test solvent for evaluating the compatibility of biologically active substances and graft copolymers
05/16/13Method for detection of ischemic strokes
05/09/13Novel inhibitor compounds of phosphodiesterase type 10a
05/09/13Novel inhibitor compounds of phosphodiesterase type 10a
05/09/13Novel inhibitor compounds of phosphodiesterase type 10a
02/07/13Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
01/31/13Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
01/17/13N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
01/03/13Novel inhibitor compounds of phosphodiesterase type 10a
12/13/12Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
12/06/12Human antibodies that bind human il-12 and methods for producing
11/22/12Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
09/27/12Human antibodies that bind human il-12 and methods for producing
09/06/12Self-emulsifying active ingredient formulation and the use of this formulation
08/23/12Human antibodies that bind human il-12 and methods for producing
08/09/12Drug formulations
07/26/12Low-molecular serine proteases inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals
07/05/12Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
06/07/12N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
05/24/12Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation ofthe serotonin 5-ht6 receptor
04/12/12Novel carboxylic acid derivatives, their preparation and use
03/29/12Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
03/29/12Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
02/16/12Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
02/16/12Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
02/16/12N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
02/09/12Method and device for determining mechanical stress load and interface effects on particles dispersed in a fluid
01/05/12Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
12/29/11Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
12/22/11Dosage forms with improved bioavailability
10/27/11Method for evaluating the solubility of a crystalline substance in a polymer
10/20/11Amyloid-beta binding proteins
10/20/11Substituted oxindol derivatives and medicaments containing the same
10/06/11Novel small molecule potentiators of metabotropic glutamate receptors i
10/06/11Novel small molecule potentiators of metabotropic glutamate receptors
08/25/11Methods for treating psoriasis
07/28/11Pharmaceutical dosage form comprising polymeric carrier composition
07/21/11Novel carboxylic acid derivatives, their preparation and use
06/30/11Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
06/16/11Ibuprofen and narcotic analgesic compositions
06/16/11Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
06/09/11Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
06/02/11Method for the treatment of amyloidoses
05/26/11Human antibodies that bind human il-12 and methods for producing
05/26/11Substituted oxindole derivatives and their use as vasopressin receptor ligands
05/19/11Modulators of 5-ht receptors and methods of use thereof
05/19/11Pyrimidine compounds and use thereof
05/05/11Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
05/05/111-(7-(hexahydropyrrolo [3, 4-c] pyrrol-2 (1h)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3)
04/28/11Antineoplastic peptides
04/21/115,6-disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases
04/21/115-halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases
03/31/11Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
03/31/11Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
03/24/11Substituted oxindole derivatives, drugs containing said derivatives and the use thereof
Patent Packs
03/24/11Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
03/24/11Low-molecular serine proteases inhibitors comprising polyhydroxy-alkyl and polyhydroxy-cycloalkyl radicals
03/10/11Carboxamide compounds and their use as calpain inhibitors
01/13/11Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
01/13/11Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
01/06/11Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
12/23/10Bone morphogenetic protein (bmp)-binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and use of same
12/23/10Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
12/09/10Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor
12/09/101,2,4,-triazin-3,5-dione compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
12/09/10Method for the treatment of amyloidoses
11/25/10Pharmaceutical dosage form comprising a liquid or flowable core composition
11/25/10Modulators of 5-ht receptors and methods of use thereof
11/11/10Carboxamide compounds and their use as calpain inhibitors
10/28/10Substituted oxindol derivatives, medicaments containing said derivatives and use thereof
Patent Packs
09/30/10Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
07/08/10Abuse resistant melt extruded formulation having reduced alcohol interaction
07/08/10Aß(x - 38 .. 43) oligomers, and processes, compositions, and uses thereof
06/17/10Device and forming moulded bodies from a mouldable mass
06/17/10Substituted benzimidazolone derivatives, medicaments comprising them and their use
06/10/10Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
06/03/10Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
05/13/10Solid dosage form with a film containing an active substance, as well as its production
03/25/10High power rotational cycle moulding
02/25/10Nanocrystals for use in topical cosmetic formulations and production thereof
02/25/10Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
12/31/09Pyridazine compounds as glycogen synthase kinase 3 inhibitors
12/24/09Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands
12/24/09Abuse resistant melt extruded formulation having reduced alcohol interaction
12/17/09Human antibodies that bind human il-12 and methods for producing
12/17/09Process for producing a solid dispersion of an active ingredient
12/10/09Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor
12/10/09Process for producing a solid dispersion of an active ingredient
11/05/09Production of enveloped pharmaceutical dosage forms
10/29/09Human antibodies that bind human il-12 and methods for producing
10/22/094-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
09/03/09Composition and dosage form comprising a solid or semi-solid matrix
07/23/09Substituted oxindole derivatives, medicaments containing the latter and use thereof
07/09/09Human antibodies that bind human il-12 and methods for producing
06/04/09Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
06/04/09Solid dispersion product containing n-aryl urea-based compound
05/21/09Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
02/26/09Substituted n-heterocyclic compounds and their use as dopamine d3 receptor ligands







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Abbott Gmbh & Co Kg in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Abbott Gmbh & Co Kg with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';